<DOC>
	<DOCNO>NCT00001462</DOCNO>
	<brief_summary>Alpha 1-antitrypsin-deficient individual develop severe destructive lung disease much earlier lung function decline faster general population individual chronic obstructive lung disease . This study design well understand pathogenesis lung destruction alpha 1-antitrypsin deficient individual characterize pathobiology early lung destruction . To accomplish intend use bronchoalveolar lavage determine quantify factor initiate sustain lung inflammation alpha 1-antitrypsin deficient individual lung function force expiratory volume one second ( FEV1 ) great 50 % predict .</brief_summary>
	<brief_title>Characterization Pathobiology Early Lung Destruction Alpha 1-Antitrypsin Deficient Individuals</brief_title>
	<detailed_description>Alpha 1-antitrypsin-deficient individual develop severe destructive lung disease much earlier lung function decline faster general population individual chronic obstructive lung disease . This study design well understand pathogenesis lung destruction alpha 1-antitrypsin deficient individual characterize pathobiology early lung destruction . To accomplish intend use bronchoalveolar lavage determine quantify factor initiate sustain lung inflammation alpha 1-antitrypsin deficient individual lung function force expiratory volume one second ( FEV1 ) great 50 % predict .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Emphysema</mesh_term>
	<mesh_term>Pulmonary Emphysema</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
	<mesh_term>Alpha 1-Antitrypsin</mesh_term>
	<mesh_term>Protein C Inhibitor</mesh_term>
	<criteria>Any alpha 1 antitrypsindeficient individual . 1865 year old . FEV1 great 1 equal 50 percent predict ( forced expiratory volume ) . Study participation require one year . A total four bronchoscopies perform year period . Methacholine challenge test perform begin end study assess degree reactive airway disease . Pneumococcal annual influenza vaccine give . No prolastin within one year prior start study . No oral systemic corticosteroid within 30 day prior start study . No allergy topical local anesthetic ( i.e. , lidocaine ) . No pregnancy . No HIV positive patient . No Hepatitis B/C virus positive patient . No patient condition associate immunodeficiency . No patient presence significant cardiac disease . No patient presence uncorrected bloodclotting disorder . No patient oxygen home regular basis . No adverse reaction methacholine .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 1999</verification_date>
	<keyword>Alpha 1-Antitrypsin Deficiency</keyword>
	<keyword>Emphysema</keyword>
	<keyword>Genetic Diseases</keyword>
	<keyword>Inflammation</keyword>
	<keyword>Nitric Oxide</keyword>
	<keyword>Protease</keyword>
</DOC>